title: [The topical treatment of allergic and vasomotor rhinitis: the role of beclomethasone dipropionate].
abstract: Allergic rhinitis is the most frequent allergic disorder, as its prevalence is more than 20% in the general population. Non-allergic rhinitis has similar symptoms, but pathogenic mechanisms are non-IgE-mediated. Anyway, both diseases share a common inflammatory pathway, thus anti-inflammatory drugs represent the optimal therapeutical option. Beclomethasone dipropionate (BDP) is a corticosteroid that is long time available both as intranasal spray and aerosol solution. The present review aims at analysing the most relevant and recent studies concerning the BDP use in allergic and non-allergic rhinitis. The research was performed using Medline and Scopus database, key words were: allergic and non-allergic rhinitis, beclomethasone (last access 31st July 2014). BDP is a corticosteroid with proved efficacy in the treatment of rhinitis, both as spray and aerosol. Safety issue has been satisfactory explored, thus BDP is usually safe and well tolerated.
authors.forename: Giorgio
authors.initials: G
authors.lastname: Ciprandi
authors.forename: Giovanni A
authors.initials: GA
authors.lastname: Rossi
mesh_terms: D000281:Administration, Intranasal; D000287:Administration, Topical; D000336:Aerosols; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001507:Beclomethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D065631:Rhinitis, Allergic / Q000188:drug therapy* / Q000503:physiopathology; D012223:Rhinitis, Vasomotor / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000336:Aerosols; D000893:Anti-Inflammatory Agents; D001507:Beclomethasone